Responses
Regular and young investigator award abstracts
Checkpoint blockade therapy
229 Discovery of ganglioside GM2 activator as a novel proteomic biomarker associated with response to treatment in first-line melanoma subjects treated with PD-1 immunotherapy
Compose a Response to This Article
Other responses
No responses have been published for this article.